1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cardiometabolic Drug News DECEMBER 2014

Cardiometabolic Drug News DECEMBER 2014

  • December 2014
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Brief - Analyses Show Novartis' LCZ696 Could Change Course Of HF For Patients
Industry Brief - Intarcia/Servier Sign Ex-US Partnership For ITCA 650 In Diabetes
Industry Brief - Cardiome/Aspen Sign South African Brinavess Commercialisation Agreement
Industry Brief - BI To Not Exercise Option For Athera's Cardiovascular Antibody
Industry Brief - EC Approves Lilly's Trulicity For Type II Diabetes
Industry Brief - FDA Accepts Evolocumab BLA For Review
Industry Brief - Lilly's Trulicity Available In US Pharmacies
Industry Brief - Merck Submits Omarigliptin NDA In Japan For Type II Diabetes
Industry Brief - Orexigen Receives Allowance Of New US Patent For Contrave
Industry Brief - Surepost Gains Japanese Approval For Use In Type II Diabetes
Industry Brief - CHMP Issues Positive Opinion On Victoza Label Expansion
Industry Brief - Two Additional US Patents Issued For Vivus' Qsymia
Industry Brief - Mylan Challenges Esmolol Patents
Industry Brief - Teva Launches Generic Exforge HCT Tablets In US
Industry Brief - Positive Data From Liraglutide Phase IIIa Study Highlighted At ObesityWeek 2014
Industry Brief - CSL Launches AEGIS-I Phase IIb Study Of CSL112
Industry Brief - Matinas Granted US Patent Allowance Covering MAT9001
Industry Brief - Brinavess Asia-Pacific Phase III Study Meets Primary Endpoint
Industry Brief - BI Initiates US Sites In Global Phase III Trial of Idarucizumab In Patients Taking Pradaxa
Industry Brief - AstraZeneca Begins Preclinical Development Programme For Brilinta Reversal Agent
Industry Brief - DM199 Phase IIa Trial Meets Primary But Not Secondary Endpoints In Type II Diabetes
Industry Brief - Final Analysis From Proteo's Elafin Phase II Study Completed In CABG
Industry Brief - Positive Results Reported From First Part Of Andexanet Alfa/Eliquis Phase III Study
Industry Brief - Vytorin Significantly Reduced CV Events Over Simvastatin Alone In ACS Patients

Table Of Contents

Cardiometabolic Drug News DECEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.